Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1Breast 1

Conditions

Hypertension 3Diabetes Mellitus, Type 2 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Pituitary ACTH Hypersecretion 2Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Adrenocortical Carcinoma 1Adrenal Cortex Neoplasms 1

Interventions

Gemcitabine 153Fluorouracil 45Capecitabine 45130-nm albumin-bound paclitaxel 43Oxaliplatin 42Albumin-Bound Paclitaxel 39Leucovorin 31Erlotinib Hydrochloride 30pembrolizumab 23Radiotherapy 22Irinotecan 22Radiosurgery 20Bevacizumab 19Docetaxel 17Cyclophosphamide 17Taxes 13Cisplatin 13Cetuximab 13folfirinox 12Nivolumab 11Surgical Procedures, Operative 7Paclitaxel 7Ipilimumab 7dehydroftorafur 6Standard of Care 6Radiation 6Magnetic Resonance Spectroscopy 6spartalizumab 5ruxolitinib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Pancreatic Neoplasms × relacorilant × Clear all
NCT04329949 2023-11-18

RELIANT

Corcept Therapeutics

Phase 3 Terminated
43 enrolled 17 charts
Gastrointestinal

Pancreatic Neoplasms

NCT02762981 2022-12-06

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Corcept Therapeutics

Phase 1/2 Completed
85 enrolled 24 charts
BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡